Leerink Partnrs Brokers Lower Earnings Estimates for VRTX

Key Points

• Leerink Partners has lowered their Q3 2025 earnings per share estimates for Vertex Pharmaceuticals to $4.36, down from $4.38, while maintaining a "Strong-Buy" rating on the stock.
• Other research firms have also adjusted their price targets, with Evercore ISI reducing their objective from $510 to $475 and Royal Bank of Canada from $430 to $405.
• Vertex Pharmaceuticals recently reported better-than-expected earnings of $4.52 per share for the last quarter, surpassing the consensus estimate of $4.24.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a research note issued to investors on Thursday, September 25th. Leerink Partnrs analyst D. Risinger now forecasts that the pharmaceutical company will post earnings per share of $4.36 for the quarter, down from their prior estimate of $4.38. Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

Several other research firms also recently weighed in on VRTX. Evercore ISI cut their price objective on Vertex Pharmaceuticals from $510.00 to $475.00 and set an "outperform" rating on the stock in a report on Thursday, September 11th. Royal Bank Of Canada cut their price objective on Vertex Pharmaceuticals from $430.00 to $405.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 5th. Raymond James Financial began coverage on Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a "market perform" rating on the stock. Scotiabank cut their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 5th. Finally, Leerink Partners raised Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and cut their price objective for the company from $458.00 to $456.00 in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $493.81.

Vertex Pharmaceuticals Stock Up 1.0%

NASDAQ VRTX opened at $385.73 on Monday. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $519.88. The company has a market cap of $98.90 billion, a price-to-earnings ratio of 27.57 and a beta of 0.44. The business's fifty day moving average is $406.00 and its 200 day moving average is $445.87.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter last year, the business posted ($12.83) EPS. Vertex Pharmaceuticals's revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was purchased at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.20% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Activest Wealth Management bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd increased its position in Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after buying an additional 45 shares in the last quarter. Access Investment Management LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $27,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at about $29,000. Finally, Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals in the 1st quarter valued at about $32,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.